阿托伐他汀在非酒精性脂肪肝治疗中的应用价值  

Application value by atorvastatin in treatment of non-alcoholic fatty liver disease

作　　者：王东旭[1] 赵艳梅[1] 蔺晶晶 王云[1] 莫乐君[1] 

机构地区：[1]玉林市第一人民医院消化内科,537000 [2]北京王府中西医结合医院急诊科

出　　处：《中国现代药物应用》2017年第1期1-3,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探究阿托伐他汀在非酒精性脂肪肝(NAFLD)治疗中的应用价值。方法 88例NAFLD患者,按照住院号的奇偶数分为观察组和对照组,各44例。对照组给予甘草酸二铵肠溶胶囊治疗,观察组患者在对照组基础上加用阿托伐他汀治疗,比较两组患者临床症状评分、肝功能、代谢情况、不良反应、脂肪肝的程度评分情况。结果与治疗前比较,两组患者治疗后临床症状明显改善(P<0.05)。治疗后,观察组疲乏(0.46±0.35)分,肝区不适(0.67±0.35)分,腹胀(1.35±0.68)分,纳差恶心(0.59±0.55)分,明显低于对照组的(0.92±0.53)、(1.01±0.67)、(1.73±0.72)、(0.93±0.65)分(P<0.05)。与治疗前比较,两组治疗后丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、谷氨酰转移酶(GGT)、总胆红素(TB)、脂肪肝程度评分下降显著(P<0.05);两组ALT、AST、GGT、TB比较差异无统计学意义(P>0.05);观察组脂肪肝程度评分(1.16±0.38)分,明显低于对照组的(1.31±0.24)分,差异有统计学意义(P<0.05)。两组组治疗后血糖(GLU)、总胆固醇(TG)、甘油三酯(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)改善程度明显优于治疗前,差异有统计学意义(P<0.05);且观察组患者治疗后GLU、TG、TC、HDL-C、LDL-C改善明显优于对照组,差异有统计学意义(P<0.05)。两组患者均无明显不良反应。结论阿托伐他汀治疗非酒精性脂肪肝的临床疗效显著,不良反应少,值得临床推广与应用。Objective To investigate application value by atorvastatin in treatment of non-alcoholic fatty liver disease（NAFLD）. Methods A total of 88 NAFLD patients were divided by admission order into observation group and control group, with 44 cases in each group. The control group received diammonium glycyrrhizinate enteric-coated capsules for therapy, and the observation group also received additional atorvastatin for treatment. Comparison was made on clinical symptom score, liver function, metabolic status, adverse reactions and fatty liver degree score between the two groups. Results Comparing with those before treatment, both groups had obviously improved clinical symptoms after treatment（P〈0.05）. After treatment, the observation group had fatigue score as（0.46±0.35） points, liver discomfort score as（0.67±0.35） points, abdominal distension score as（1.35±0.68） points, poor appetite and nausea score as（0.59±0.55） points, which were all much lower than（0.92±0.53）,（1.01±0.67）,（1.73±0.72） and（0.93±0.65） points in the control group（P〈0.05）. Comparing with those before treatment, both groups had obviously decreased alanine aminotransferase（ALT）, aspartate aminotransferase（AST）, glutamyltransferase（GGT）, total bilirubin（TB） and fatty liver degree score（P〈0.05）. There was no statically significant difference of ALT, AST, GGT and TB between the two groups（P〉0.05）. The observation group had much lower fatty liver degree score as（1.16±0.38） points than（1.31±0.24） points in the control group, and the difference had statistical significance（P〈0.05）. Both groups had obviously better improvements of blood glucose（GLU）, total cholesterol（TC）, triglyceride（TG）, high density lipoprotein cholesterol（HDL-C）, and low density lipoprotein cholesterol（LDL-C） after treatment than those before treatment, and the difference had statistical significance（P〈0.05）. The observation group had all better improvements of GLU, T

关 键 词：阿托伐他汀 非酒精性脂肪肝 应用价值 

分 类 号：R575.5[医药卫生—消化系统]